Imanishi, Seiichi
Naoi, Yasuto http://orcid.org/0000-0002-6090-0137
Shimazu, Kenzo
Shimoda, Masafumi
Kagara, Naofumi
Tanei, Tomonori
Miyake, Tomohiro
Kim, Seung Jin
Noguchi, Shinzaburo
Funding for this research was provided by:
Externally Sponsored Research (NCR-16-12580)
Article History
Received: 16 September 2018
Accepted: 22 December 2018
First Online: 3 January 2019
Compliance with ethical standards
:
: Shinzaburo Noguchi has been an adviser for Taiho, AstraZeneca, and Novartis and has received research funding for this study from AstraZeneca and for other studies from Sysmex, Novartis, Chugai, Daiichi-Sankyo, Kyowa-Kirin, Takeda, Pfizer, Ono, Taiho, and Eisai and honoraria from AstraZeneca, Novartis, Pfizer, Chugai, Takeda, Sysmex, Nippon Kayaku, and Ono. Yasuto Naoi has received research funding for this study from AstraZeneca and honoraria from Sysmex. Naofumi Kagara has received honoraria from AstraZeneca and Novartis. Masafumi Shimoda has received research funding for other studies from Novartis and AstraZeneca and honoraria from Chugai, Eisai, Novartis, and Takeda. Kenzo Shimazu has received honoraria from AstraZeneca, Chugai, and Sysmex. Seung Jim Kim has received honoraria from AstraZeneca, Chugai, Eisai, Kyowa-Kirin, Novartis, Pfizer, Shimadzu, Taiho, and Takeda. The other authors declare no conflicts of interest.
: This study complies with the current relevant laws of and guidelines for Japan.
: The study protocol was approved by the Ethical Review Board of Osaka University Hospital, and informed consent was obtained from each patient before tumor biopsy.